Nimesulide regulatory update

EMA's CHMP recommended restricting the use of nimesulide-containing medicines to the treatment of acute pain and primary dysmenorrhoea based on concerns of liver toxicity with long-term use. The committee concluded that the agents should no longer be used to treat painful osteoarthritis citing that the chronic nature of the condition may increase the risk of long-term treatment, and as a result, increase the risk of liver injury. ...